428 related articles for article (PubMed ID: 27702796)
1. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
3. Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
Castle PE; Glass AG; Rush BB; Scott DR; Wentzensen N; Gage JC; Buckland J; Rydzak G; Lorincz AT; Wacholder S
J Clin Oncol; 2012 Sep; 30(25):3044-50. PubMed ID: 22851570
[TBL] [Abstract][Full Text] [Related]
4. Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
Befano B; Wentzensen N; Lorey T; Poitras N; Cheung LC; Schiffman M; Clarke MA; Cohen C; Kinney W; Locke A; Castle PE
Gynecol Oncol; 2024 May; 184():89-95. PubMed ID: 38301311
[TBL] [Abstract][Full Text] [Related]
5. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
6. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
7. Five-year risk of CIN3 after short-term HPV-DNA negativity in cytology-negative women: a population-based cohort study.
Del Mistro A; Giorgi Rossi P; Frayle H; Pasquale L; Campari C; Ronco G; Zorzi M
BJOG; 2019 Oct; 126(11):1365-1371. PubMed ID: 31356722
[TBL] [Abstract][Full Text] [Related]
8. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.
Bulkmans NW; Berkhof J; Rozendaal L; van Kemenade FJ; Boeke AJ; Bulk S; Voorhorst FJ; Verheijen RH; van Groningen K; Boon ME; Ruitinga W; van Ballegooijen M; Snijders PJ; Meijer CJ
Lancet; 2007 Nov; 370(9601):1764-72. PubMed ID: 17919718
[TBL] [Abstract][Full Text] [Related]
10. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
[TBL] [Abstract][Full Text] [Related]
11. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
Dillner J; Rebolj M; Birembaut P; Petry KU; Szarewski A; Munk C; de Sanjose S; Naucler P; Lloveras B; Kjaer S; Cuzick J; van Ballegooijen M; Clavel C; Iftner T;
BMJ; 2008 Oct; 337():a1754. PubMed ID: 18852164
[TBL] [Abstract][Full Text] [Related]
12. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
[TBL] [Abstract][Full Text] [Related]
14. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.
Kitchener HC; Almonte M; Thomson C; Wheeler P; Sargent A; Stoykova B; Gilham C; Baysson H; Roberts C; Dowie R; Desai M; Mather J; Bailey A; Turner A; Moss S; Peto J
Lancet Oncol; 2009 Jul; 10(7):672-82. PubMed ID: 19540162
[TBL] [Abstract][Full Text] [Related]
15. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer.
Inturrisi F; Lissenberg-Witte BI; Veldhuijzen NJ; Bogaards JA; Ronco G; Meijer CJLM; Berkhof J
Int J Cancer; 2021 Jan; 148(2):320-328. PubMed ID: 32663316
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.
Castle PE; Schiffman M; Wheeler CM; Wentzensen N; Gravitt PE
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1675-81. PubMed ID: 20615885
[TBL] [Abstract][Full Text] [Related]
17. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
[TBL] [Abstract][Full Text] [Related]
18. Assessment of HPV DNA test value in management women with cytological findings of ASC-US, CIN1 and CIN2.
Pajtler M; Milicić-Juhas V; Milojković M; Topolovec Z; Curzik D; Mihaljević I
Coll Antropol; 2010 Mar; 34(1):81-6. PubMed ID: 20432737
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
Zhang Q; Dong L; Hu S; Feng R; Zhang X; Pan Q; Ma J; Zhang L; Zhao X; Sankaranarayanan R; Qiao Y; Zhao F
Int J Cancer; 2017 Sep; 141(6):1110-1119. PubMed ID: 28560716
[TBL] [Abstract][Full Text] [Related]
20. Detection of precancerous cervical lesions is differential by human papillomavirus type.
Safaeian M; Schiffman M; Gage J; Solomon D; Wheeler CM; Castle PE
Cancer Res; 2009 Apr; 69(8):3262-6. PubMed ID: 19351830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
